The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Open accessAbstract
BACKGROUND: The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established. METHODS: Patients received dasatinib with 8 cycles of alternating hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and high‐dose cytarabine and methotrexate. Patients in complete remission (CR) continued maintenance dasatinib, vincristine, and prednisone for 2 years, which was followed by dasatinib indefinitely. Patients eligible for allogeneic stem cell transplantation (SCT) received it during their first CR. RESULTS: Seventy‐two patients with a median age of 55 years (range, 21‐80 years) were treated; 69 (96%) achieved CR. Among them, 57 (83%) achieved cytogenetic CR after 1 cycle, and 64 (93%) achieved a major molecular response at a median of 4 weeks (range, 2‐38 weeks). Sixty‐five patients (94%) were negative for minimal residual disease assessed by flow cytometry at a median of 3 weeks (range, 2‐37 weeks). Dasatinib‐related grade 3 and 4 adverse events included bleeding, pleural/pericardial effusions, and elevated transaminases. With a median follow‐up of 67 months (range, 33‐97 months), 33 patients (46%) were alive, and 30 (43%) were in CR; 12 underwent allogeneic SCT. Thirty‐nine patients died (3 at induction, 19 after relapse, 7 after SCT performed during first CR, and 10 during CR). The median disease‐free survival and overall survival were 31 (range, 0.3‐97 months) and 47 months (range, 0.2‐97 months), respectively. Seven relapsed patients had BCR‐ABL kinase domain mutations, including 4 with T315I. CONCLUSIONS: A combination of chemotherapy with dasatinib is effective in achieving long‐term remission for patients with newly diagnosed Ph + ALL. Cancer 2015;121:4158–4164. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citation
Cited by
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5157 · Cited by 33
Self-citation
Metadata
- Authors
- Ravandi, F., O'Brien, S. M., Cortes, J. E., Thomas, D. M., Garris, R., Faderl, S., Burger, J. A., Rytting, M. E., Ferrajoli, A., Wierda, W. G., Verstovsek, S., Champlin, R., Kebriaei, P., McCue, D. A., Huang, X., Jabbour, E., Garcia‐Manero, G., Estrov, Z., & Kantarjian, H. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-08-26
- Volume
- 121
- Issue
- 23
- Pages
- 4158-4164
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1673031009
- Cited by
- 227
- References
- 1
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1002/cncr.29646
- The paper
- Ravandi, F., O'Brien, S. M., Cortes, J. E., Thomas, D. M., Garris, R., Faderl, S., Burger, J. A., Rytting, M. E., Ferrajoli, A., Wierda, W. G., Verstovsek, S., Champlin, R., Kebriaei, P., McCue, D. A., Huang, X., Jabbour, E., Garcia‐Manero, G., Estrov, Z., & Kantarjian, H. M. (2015). Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.29646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.